2nd Generation Smallpox Vaccine
Solicitation number 6D024-203934/A
Publication date
Closing date and time 2021/01/11 14:00 EST
Description
Trade Agreement: Canadian Free Trade Agreement (CFTA) Tendering Procedures: Generally only one firm has been invited to bid Non-Competitive Procurement Strategy: Exclusive Rights Comprehensive Land Claim Agreement: No Vendor Name and Address: EMERGENT BIOSOLUTIONS CANADA INC. 155 Innovation Drive Winnipeg Manitoba Canada R3T5Y3 Nature of Requirements: Purpose of ACAN: Public Services and Procurement Canada proposes to negotiate a contract with Emergent BioSolutions Inc. on behalf of the Public Health Agency of Canada (PHAC) for the purchase of ACAM2000®. Definition of Requirement: ACAM2000® is indicated for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. Although smallpox disease is currently considered to be eradicated, PHAC is procuring a stockpile of the vaccine to immunize Canadians against smallpox disease should a risk ever arise where smallpox is intentionally or unintentionally released. Quantities: The estimated quantity for the firm delivery is 5,800 vials (580,000 treatment courses), with 4,600 vials (460,000 treatment courses) in optional quantities. Term of Contract: Contract award to March 31, 2024. Evaluation Criteria: 1) The vaccine must have current regulatory approval by one of the following organizations: Health Canada (HC), the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA). 2) The vaccine must be approved by HC or the US FDA or EMA or UK MHRA with an indication for active immunization against smallpox disease. 3) The vaccine must be supplied in multiple-dose glass vials containing lyophilized powder (freeze-dried vaccine). At a storage temperature of -15°C to -25°C, the vaccine must have a minimum of sixteen (16) years of shelf life from the date of manufacture of the final product. 4) The Vendor must supply the initial requirement of 1,800 vials with a delivery date no later than March 31, 2021, with at least 16 years of shelf life. 5) The vaccine must be supplied with the required amount of diluent, bifurcated needles and tuberculin syringes for the initial deliveries as well as the required amount to replace up to 1,040,000 treatment courses for duration of the vaccine 16 year shelf life. Delivery: 1,800 vials on or before March 31, 2021; 2,000 vials on or before March 31, 2022; and 2,000 vials on or before March 31, 2023. As and when required for the optional quantities. Limited Tendering Reason: In accordance with Government Contract Regulations (GCRs Part 1 - Conditions of Contract Entry - Bids - 6.(d)) Emergent BioSolutions Inc., is the only known supplier of a 2nd generation smallpox vaccine approved with either HC, the FDA, EMA, or MHRA for the treatment of human smallpox disease. Delivery Date: Above-mentioned You are hereby notified that the government intends to negotiate with one firm only as identified above. Should you have any questions concerning this requirement, contact the contracting officer identified above. An Advance Contract Award Notice (ACAN) allows departments and agencies to post a notice, for no less than fifteen (15) calendar days, indicating to the supplier community that it intends to award a good, service or construction contract to a pre-identified contractor. If no other supplier submits, on or before the closing date, a Statement of Capabilities that meets the requirements set out in the ACAN, the contracting authority may then proceed with the award. However, should a Statement of Capabilities be found to meet the requirements set out in the ACAN, then the contracting authority will proceed to a full tendering process. Suppliers who consider themselves fully qualified and available to provide the services/goods described herein, may submit a statement of capabilities in writing to the contact person identified in this Notice on or before the closing date of this Notice. The statement of capabilities must clearly demonstrate how the supplier meets the advertised requirements. The PWGSC file number, the contracting officer's name and the closing date of the ACAN must appear on the outside of the envelope in block letters or, in the case of a facsimile transmission, on the covering page. The Crown retains the right to negotiate with suppliers on any procurement. Documents may be submitted in either official language of Canada.
Contract duration
Refer to the description above for full details.
Trade agreements
-
Canadian Free Trade Agreement (CFTA)
Reason for limited tendering
A contracting officer can use limited tendering for specific reasons outlined in the applicable trade agreements. The reason for this contract is described below:
-
Exclusive Rights
Contact information
Contracting organization
- Organization
-
Public Works and Government Services Canada
- Address
-
11 Laurier St, Phase III, Place du PortageGatineau, Quebec, K1A 0S5Canada
- Contracting authority
- Terrasses de la Chaudière 5th Floor
- Phone
- ( ) - ( )
- Email
- TPSGC.Vaccin-Vaccine.PWGSC@tpsgc-pwgsc.gc.ca
- Fax
- () -
- Address
-
10 Wellington StreetGatineau, Quebec, K1A 0S5
Buying organization(s)
- Organization
-
Public Health Agency of Canada
- Address
-
130 Colonnade RoadOttawa, Ontario, K1A 0K9Canada
Bidding details
Details for this tender opportunity are provided in the Description tab.
Please contact the contracting officer to get the full solicitation documentation, access information on how to bid, or if you have any questions regarding this tender opportunity.
Note that there may be fees to access the documents or bid. These should be outlined in the Description tab.
We recommend that you contact the contracting officer as soon as possible, as there may be deadlines for receiving questions.